On September 19, 2022, Nascent Biotech Inc. (the "Company") reported that it entered into an agreement with YA II PN, Ltd. ("YA II"), an unrelated third party (Filing, 8-K, Nascent Biotech, SEP 19, 2022, View Source [SID1234619690]). YA II has already loaned the Company $500,00. The second tranche of $500,000.00 will be paid at Closing of this transaction. In connection with the loan, the Company is issuing YA II its second Convertible Debenture (the "Second Debenture"). The Second Debenture is for $500,000.00, has a maturity date of one year and is due on September 19, 2023. The interest rate is six percent (6%) per annum. The Debenture may be converted at the lesser of $0.30 per share or eighty percent (80%) of the lowest VWAP of the Company’s common stock for ten consecutive trading days immediately prior to the conversion date. The Debenture may be prepaid in accordance with the terms set forth in the Debenture. The Debenture also contains certain representations, warranties, covenants, and events of default including, among other things, if the Company becomes delinquent in its periodic report filings with the Securities and Exchange Commission (the "SEC"). If an event of default occurs, the amount of the principal and interest rate due under the Debentures increases.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

YA II will not affect any conversion which will result in its holding more than 9.99% of our common stock. The Debenture provides for certain penalties for failure to timely deliver stock and contains other protective provisions for YA II. As required, the Company filed its Registration Statement on Form S-1 on September 19, 2022. As required under the terms of this financing, to date, $1,000,000 of the total proposed loan amount of $1,500,000 principal amount of the Debenture has been received. The final tranche of $500,000 will be due upon the effectiveness of the Registration Statement.

The foregoing descriptions of the terms of the Debenture do not purport to be complete and are qualified in their entirety by the complete text of the documents attached as Exhibit 4.1 to this Current Report on Form 8-K.

On September 19, 2022 Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH) reported that its Board of Directors has authorized a $250 million capital return program consisting of the following three elements (Press release, Theravance, SEP 19, 2022, View Source [SID1234619676]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Theravance Biopharma has executed a definitive agreement with GSK to purchase all of GSK’s equity stake in Theravance Biopharma, constituting approximately 9.6 million shares at $9.75 per share, with a closing date of September 20, 2022.
The Company intends to commence a Dutch auction tender offer to purchase approximately $95 million of its ordinary shares in the near term.
The Company plans to enter into an Open Market Stock Repurchase Plan to facilitate the repurchase of approximately $60 million of its ordinary shares in open market purchases subsequent to the completion of the tender offer, with a goal to complete this program by the end of 2023.
Certain Information Regarding the Tender Offer

The tender offer for the Company’s ordinary shares described above has not yet commenced. This document is for informational purposes only, is not a recommendation and is neither an offer to purchase nor a solicitation of an offer to sell shares or any other securities. At the time the tender offer is commenced, the Company will file with the SEC a Tender Offer Statement on Schedule TO. The solicitation and the offer to purchase the shares will only be made pursuant to the offer to purchase, a related letter of transmittal, and related documents filed with such Schedule TO. COMPANY SHAREHOLDERS ARE URGED TO READ THE TENDER OFFER STATEMENT (INCLUDING AN OFFER TO PURCHASE, THE RELATED LETTER OF TRANSMITTAL AND CERTAIN OTHER TENDER OFFER DOCUMENTS), AS IT MAY BE AMENDED FROM TIME TO TIME, WHEN SUCH DOCUMENTS BECOME AVAILABLE, BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION THAT SHOULD BE READ CAREFULLY BEFORE ANY DECISION IS MADE WITH RESPECT TO THE TENDER OFFER. Company shareholders and other investors can obtain the Tender Offer Statement and other filed documents for free at the SEC’s website at www.sec.gov. Copies of the documents filed with the SEC by the Company will be available free of charge on the Company’s website, investor.theravance.com, under "SEC Filings" or by contacting the Company’s investor relations department at (650) 808-4045. In addition, Company noteholders may obtain free copies of the tender offer materials by contacting the dealer manager for the tender offer that will be named in the Tender Offer Statement.

On September 19, 2022 Regen BioPharma, Inc. (OTC PINK: RGBP) and (OTC PINK: RGBPP) reported that filing of a provisional patent application with the USPTO entitled "Dual Checkpoint Inhibitor Aptamer Based Therapeutics" (Press release, Regen BioPharma, SEP 19, 2022, View Source [SID1234619675]). The application covers novel compositions of matter capable of acting as conventional checkpoint inhibitor drugs while simultaneously silencing genes which regulate T cells and cancer cells such as NR2F6 and Survivin. The Company believes that this platform technology is the first combination of an immunotherapy and a gene silencing agent in a single drug.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Aptamers are short DNA or RNA sequences which can function as antibodies – they recognize specific proteins and bind to them. This new technology takes advantage of the fact that the Company can put its proprietary RNA or DNA sequences which code for inhibitory RNAs on one end of an aptamer while using the other end of the aptamer to bind to, and thus inhibit, a traditional immune checkpoint such as PD-1. Once the aptamer is internalized into the cell, the proprietary DNA or RNA sequence is converted to an inhibitory RNA which targets other genes involved in T cell function or cancer growth leading to a two-pronged approach to T cell activation or cancer-killing.

"Our Company has been working on RNA therapeutics for several years, including being granted a U.S. patent for survivin-based RNA vaccines, as well as gene silencing of NR2F6," said Dr. David Koos, CEO and Chairman of the Company. "We believe the merger of this technology with checkpoint inhibitors, and the resulting platform technology, will result in development of numerous potent therapeutic candidates."

On September 19, 2022 IDEAYA Biosciences, Inc. ( Nasdaq:IDYA) reported the closing of its underwritten public offering of 8,761,905 shares of its common stock at a public offering price of $10.50 per share, before underwriting discounts and commissions, including the exercise in full by the underwriters of their option to purchase up to an additional 1,142,857 shares of common stock in the offering (Press release, Ideaya Biosciences, SEP 19, 2022, View Source [SID1234619674]). The gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by IDEAYA, were approximately $92.0 million.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

J.P. Morgan, Jefferies, Citigroup and Guggenheim Securities acted as joint book-running managers for the offering. Wedbush PacGrow acted as lead manager for the offering.

The public offering was made by IDEAYA pursuant to a shelf registration statement on Form S-3 that was previously filed with and declared effective by the U.S. Securities and Exchange Commission, or the SEC. The offering was made only by means of a written prospectus and prospectus supplement that form a part of the registration statement. A final prospectus supplement and accompanying prospectus relating to the offering has been filed with the SEC and is available on the SEC’s website at View Source Copies of the final prospectus supplement and the accompanying prospectus relating to the offering may also be obtained by request from: J.P. Morgan, by mail at J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, or by telephone at 866-803-9204, or by email at [email protected]; Jefferies, by mail at Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, New York, NY 10022, or by telephone at 877-547-6340 or 877-821-7388, or by email at [email protected]; Citigroup, by mail at Citigroup Global Markets Inc., c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, or by telephone at 1-800-831-9146; or Guggenheim Securities, by mail at Guggenheim Securities, LLC, Attention: Equity Syndicate Department, 330 Madison Avenue, New York, NY 10017, or by telephone at (212) 518-5548 or by email at [email protected].

This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.

On September 19, 2022 SHINE Technologies, a next-generation fusion technology company, and Radiopharm Theranostics (ASX:RAD), a developer of a world-class platform of radiopharmaceutical products for both diagnostic and therapeutic uses, reported that they have entered into a clinical supply agreement (Press release, Radiopharm Theranostics, SEP 19, 2022, View Source [SID1234619672]). SHINE will supply Radiopharm with isotope non-carrier-added lutetium-177 (Lu-177).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The isotope will be used by Radiopharm in the development of its clinical pipeline of diagnostic and therapeutic radiopharmaceutical products. Lu-177 is an important isotope utilized in multiple programs across Radiopharm’s portfolio.

Nearly everyone has been affected by cancer. SHINE’s efforts are about prolonging lives of those affected most directly.

"One way or another, nearly everyone has been affected by cancer. SHINE’s efforts in lutetium-177 are all about prolonging the lives of those affected most directly," said Chris Vessell, general manager of SHINE’s Therapeutics Division. "We are excited that our isotopes will play a critical role in Radiopharm Theranostics’ programs that aim to revolutionize cancer treatment."

SHINE, an emerging leader in the production of this medical radioisotope, intends to be the industry’s only vertically integrated producer of Lu-177, aiming to provide a reliable and scalable supply independent of current supply-chain restraints."

"Ensuring supply of key isotopes continues to be a priority for our team, allowing us to accelerate our clinical programs unimpeded," said Riccardo Canevari, CEO and managing director of Radiopharm Theranostics. "Lutetium-177 is required for three of our more advanced assets and this clinical supply agreement with SHINE, an experienced player in nuclear technology, is another important step in de-risking our business plan."